Antipsychotic Long-acting Injections

Antipsychotic Long-acting Injections (2 ed.)

Edited by Peter Haddad, Tim Lambert, and John Lauriello

Previous Edition (1 ed.)

Abstract

This book comprehensively reviews clinical practice and research findings concerning antipsychotic long-acting injections (LAIs) and should be relevant to academics and a range of healthcare professionals. The authors are all international experts in their fields. The book starts by reviewing the clinical course of schizophrenia and antipsychotic non-adherence. This is followed by chapters on the pharmacology of LAIs, their safety and tolerability, and the comparative effectiveness of LAIs versus oral antipsychotics. There are individual chapters on first-generation antipsychotic LAIs and each of the second-generation LAIs currently available (aripiprazole LAI, olanzapine LAI, paliperidone LAI, risperidone LAI). Further chapters discuss the use of LAI early in the course of psychosis, health professionals’ and patients’ attitudes to treatment, the importance of patient choice, prescribing patterns and determinants of LAI use by country, and the management of a specialist clinic for LAIs. The final chapter reviews the place of LAIs in current practice and highlights areas for future research. Antipsychotic LAIs are one strategy that can improve adherence and for some patients they offer greater convenience than daily oral medication. However, LAIs are not appropriate for all patients or all those with adherence problems. A recurrent message in this book is that the decision to prescribe an LAI needs to be collaborative and involve the patient. Antipsychotic medication, oral or LAI, is only one part of the treatment of schizophrenia and always needs to be combined with psychological and social treatments to provide an individualized treatment approach geared to recovery.

Bibliographic Information

Publisher:: Oxford University Press

Print Publication Date:: Mar 2016

Print ISBN-13:: 9780198729471

Published online:: Jul 2016

DOI:: 10.1093/med/9780198729471.001.0001

Authors

Peter Haddad, editor Consultant Psychiatrist, Greater Manchester West Mental Health NHS Foundation Trust, UK

Tim Lambert, editor Professor of Discipline of Psychiatry, University of Sydney, Head, Schizophrenia Treatments and Outcomes Research Group, Brain and Mind Research Institute, Sydney, Australia

John Lauriello, editor Professor and Chair, Department of Psychiatry, University of Missouri, School of Medicine, Columbia, Missouri, USA

Back to results

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.

Front Matter
Chapter 1 Antipsychotic treatment and adherence in schizophreniaChristoph U. Correll, Chris Abbott, Samuel J. Keith, and Peter Haddad
Chapter 2 Pharmacology of antipsychotic long-acting injectionsTim Lambert and David Taylor
Chapter 3 Adverse effects and antipsychotic long-acting injectionsPeter Haddad and W. Wolfgang Fleischhacker
Chapter 4 Comparative effectiveness of oral antipsychotics and long-acting injectable antipsychoticsTaishiro Kishimoto, Christoph U. Correll, and John M. Kane
Chapter 5 First-generation antipsychotic long-acting injectionsMark Taylor and Polash Shajahan
Chapter 6 Risperidone long-acting injectionPierre Chue
Chapter 7 Paliperidone long-acting injectionMuaid Ithman, Niels Beck, and John Lauriello
Chapter 8 Olanzapine long-acting injectionDieter Naber, Daniel Luedecke, and Daniel Schöttle
Chapter 9 Aripiprazole long-acting injectionGanesh Gopalakrishna, W. Wolfgang Fleischhacker, and John Lauriello
Chapter 10 Long-acting injectable antipsychotics in early psychosisRobin Emsley, Bonga Chiliza, and Laila Asmal
Chapter 11 Health professionals’ and patients’ attitudes to long-acting injectionsMaxine X. Patel
Chapter 12 Patient choice and long-acting injectable medicationMary Jane Tacchi, Jennifer Nendick, and Jan Scott
Chapter 13 Prescribing patterns and determinants of use of antipsychotic long-acting injections: an international perspectiveTim Lambert
Chapter 14 The management of a specialist clinic for long-acting injectable antipsychoticsTim Lambert
Chapter 15 The role of antipsychotic long-acting injections in clinical practicePeter Haddad, Tim Lambert, and John Lauriello
End Matter
- Index

Select your specializations: Select All / Clear Selections

Antipsychotic Long-acting Injections (2 ed.)

Edited by Peter Haddad, Tim Lambert, and John Lauriello

Abstract

Bibliographic Information

Authors

Contents